Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19478461 | 0.82 | HTR7 (0.57) | HTR7MAPK14ADRA1DHTR2CADRA1A | |
| SCHEMBL17439303 | 0.81 | HTR7 (0.56) | HTR7MAPK14ADRA1DHTR2CADRA1A | |
| SCHEMBL20197172 | 0.79 | MAPK14 (0.42) | HTR7MAPK14 | |
| SCHEMBL7232240 | 0.78 | AR (0.55) | HTR7MAPK14ADRA1DHTR2CADRA1A | |
| SCHEMBL5981398 | 0.78 | KDM4E (0.56) | HTR7 | |
| SCHEMBL10594962 | 0.78 | KDM4E (0.56) | HTR7 | |
| SCHEMBL17560828 | 0.78 | HTR7 (0.70) | HTR7 | |
| SCHEMBL7242746 | 0.77 | HTR7 (0.52) | HTR7MAPK14ADRA1DHTR2CADRA1A | |
| SCHEMBL20003794 | 0.76 | FDPS (0.36) | HTR7MAPK14CAMK2D | |
| SCHEMBL23938187 | 0.75 | HDAC4 (0.48) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | HTR7 3199/4885MAPK14 680/4885ADRA1D 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.